文献速递真菌感染

特殊生理或病理状态人群口服艾沙康唑剂量的优化:基于生理药代动力学模型的精准给药

Optimization of oral isavuconazole dose for population in special physiological or pathological state: a physiologically based pharmacokinetics model-informed precision dosing.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

本研究通过系统检索PubMed纳入25项口服艾沙康唑的药代动力学研究,建立并验证了基于生理的药代动力学模型,模拟了重度肝损伤、肥胖及1至不足6岁儿科人群的暴露特征。基于靶标 attainment 概率和累积反应分数分析,建议重度肝损伤人群维持剂量减半,肥胖和重度肝损伤人群负荷剂量为300 mg每8小时持续2天,1至不足6岁儿科患者按体重5.38 mg/kg给药。

要点

  • 重度肝损伤人群的艾沙康唑维持剂量应减半。
  • 肥胖和重度肝损伤人群负荷剂量为300 mg每8小时持续2天。
  • 1至不足6岁儿科患者建议按体重5.38 mg/kg给药。

核心结论

  • 模型预测值与观测值一致,提示艾沙康唑在其他人群中的药代动力学特征具有潜在可预测性。
  • 推荐的给药方案增进了对特殊人群使用艾沙康唑的理解。

研究设计与样本

  • 通过系统检索PubMed识别了25项口服艾沙康唑的药代动力学研究。
  • 使用WebPlotDigitizer提取浓度-时间数据,理化参数来自已发表文献和DrugBank。
  • 采用Simcyp群体模拟器进行模型开发和模拟,使用视觉预测检验和预测误差进行模型评价。
  • 进行了靶标 attainment 概率和累积反应分数分析以优化剂量。

主要发现

  • 所建立的PBPK模型在不同人群中成功验证,大多数预测浓度-时间点与观测数据一致,关键参数的预测误差可接受。
  • 预测了重度肝损伤人群、肥胖人群和1至不足6岁儿科患者的艾沙康唑药代动力学特征和参数。
  • 靶标 attainment 概率和累积反应分数分析表明,重度肝损伤人群应使用半量维持剂量。
  • 肥胖人群和重度肝损伤人群应使用300 mg每8小时持续2天的负荷剂量。
  • 对于1至不足6岁儿科患者,建议按体重5.38 mg/kg的给药方案。

关键数值与推荐

  • 重度肝损伤人群:维持剂量减半。
  • 肥胖人群和重度肝损伤人群:负荷剂量300 mg每8小时持续2天。
  • 1至不足6岁儿科患者:按体重5.38 mg/kg给药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To recommend precision dosing and improve therapeutic efficacy against invasive fungal disease, a physiologically based pharmacokinetic model (PBPK) of oral isavuconazole (ISA) was established and used to explore its disposition across populations in different physiological and pathological states. METHODS: Twenty-five pharmacokinetic (PK) studies of oral ISA were identified through a systematic search of PubMed. Concentration-time data were extracted using WebPlotDigitizer. Physiochemical parameters were obtained from published literature and DrugBank. Model development and simulation used the Simcyp population-based simulator, and visual predictive check and predictive error were used for the model evaluation. Probability of target attainment and the cumulative fraction of response analyses were performed for dose optimization. RESULTS: The developed PBPK model was successfully validated in different populations. Most predicted concentration-time points aligned with the observed data, with acceptable predictive errors for the critical parameters. We predicted the PK profiles and parameters of ISA in a population with severe hepatic impairment (HI), a population with obesity and paediatric patients aged 1 to less than 6 years old. The probability of target attainment and cumulative fraction of response analyses indicated that the population with severe HI should have half the maintenance dose. The population with obesity and population with severe HI should have a loading dose of 300 mg every 8 h for 2 days. For paediatric patients aged 1 to less than 6 years old, a weight-based dosing regimen (5.38 mg/kg) of ISA was suggested. CONCLUSION: The predicted value aligns with observations, suggesting ISA's potential predictability in PK profiles for other populations. The recommended dosing regimens increase our understanding of the use of ISA in special populations.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Zhou J, Xu B, Zheng Y, et al. Optimization of oral isavuconazole dose for population in special physiological or pathological state: a physiologically based pharmacokinetics model-informed precision dosing. J Antimicrob Chemother. 2024. PMID: 39086118. doi:10.1093/jac/dkae240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。